WO1998009955A1 - Process and novel intermediates - Google Patents

Process and novel intermediates Download PDF

Info

Publication number
WO1998009955A1
WO1998009955A1 PCT/US1997/015703 US9715703W WO9809955A1 WO 1998009955 A1 WO1998009955 A1 WO 1998009955A1 US 9715703 W US9715703 W US 9715703W WO 9809955 A1 WO9809955 A1 WO 9809955A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
substituted
formula
cycloalkyl
Prior art date
Application number
PCT/US1997/015703
Other languages
French (fr)
Inventor
Darrell R. Hutchison
Samantha K. Janisse
Michael J. Martinelli
Eric D. Moher
Kevin A. Sullivan
David L. Varie
David W. Hoard
John E. Toth
Original Assignee
Eli Lilly And Company
University Of Hawaii
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, University Of Hawaii, Wayne State University filed Critical Eli Lilly And Company
Priority to CA002263764A priority Critical patent/CA2263764A1/en
Priority to EP97941446A priority patent/EP0929535A4/en
Priority to AU43352/97A priority patent/AU4335297A/en
Priority to JP10512955A priority patent/JP2001502298A/en
Publication of WO1998009955A1 publication Critical patent/WO1998009955A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings

Definitions

  • R 7 and R ⁇ together form a C 3 -C ⁇ cycloalkyl ring;
  • R 51 and R ⁇ 2 independently are C : -C 3 alkyl;
  • halogenation examples include the addition of hydrogen halides, free radical halogenation, etc. Such methods are known in the art.
  • strong acid refers to an acid that has a pKa of 2 or less.
  • a hydrohalic acid is most suitable.
  • a preferred hydrohalic acid is hydrochloric acid.
  • Other mineral acids, such as phosphoric and sulfuric, and organic acids, such as tosic and acetic, may also be used.
  • hydrolysis conditions for preparing Compound 10 from Compound 9a can be readily determined.
  • Especially preferred hydrolysis agents are LiOH and NaOH.
  • the Pd(PPh 3 ), catalyst should be present in an amount less than about four (4) mole percent.
  • Preferred solvents for the process of Equation 7 are tetrahydrofuran, acetone, alcohols, acetonitrile, and ethyl acetate.
  • An especially preferred solvent is tetrahydrofuran .
  • the use of the allyl ester as a protecting group for carboxylic acids is well known and has been the subject of reviews. Kocienski, P. J. Protecting Groups; Georg Thieme Verlag: Stuttgart, 1994; pp 139-154; Greene, T. W.; Wuts, P. G. M.
  • Equation 7 can be run at a temperature of from about zero (0) to about seventy (70) degrees C.
  • a preferred temperature is about 25°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

This invention provides intermediates and processes useful for the preparation of crytophycin compounds.

Description

PROCESS AND NOVEL INTERMEDIATES
This invention relates to the fields of pharmaceutical and organic chemistry and provides novel intermediates and processes useful for the preparation of cryptophycin compounds .
Antimetabolites have been used for a number of years as chemotherapeutic agents in the treatment of cancer. A new class of antimetabolites, cryptophycin compounds are useful for disrupting the microtubule system and, thus, can be useful for the treatment of cancer. In order to produce sufficient quantities of these compounds, there is a need for efficient totally synthetic processes for their preparation. The novel processes and intermediates of this invention are important elements in providing an efficient route for preparing other cryptophycin intermediates. A special advantage provided is that the intermediates thus prepared have only minimal residual impurities. Ultimately, these intermediates can be linked to provide a total synthesis of cryptophycin compounds.
A number of problems must be resolved in order to accomplish a large scale total synthesis of a complex molecule such as the cryptophycin molecule. It is difficult to obtain intervening intermediates of sufficient purity, to be able to handle the materials easily and to obtain reliable yields when processes are carried out on the scale needed to obtain the quantities of compounds needed for pharmaceutical purposes.
The novel intermediates and processes of this invention accomplish some of these goals. For example, one of the processes permits removal of a protecting group to provide an intermediate that can now be isolated as a convenient white solid. The new coupling process results in unexpectedly greater yields and avoids what previously was an extra step of preparing a pentafluorophenyldiphenyl- phosphinic chloride coupling reagent. A rhodium-catalyzed process prepares a novel fragment, called Fragment C, that is useful for an alternative synthesis of cryptophycin compounds. Another process that is applicable to acid-and base sensitive products minimizes recrystallization and chromatography steps.
Thus, the processes and intermediates of this invention are important advances in the synthesis of useful cryptophycin compounds. These advances include, but are not limited to, increased efficiency, decreased cost, and improved purity.
In one aspect, this invention provides a novel intermediate of Formula XII
Figure imgf000005_0001
XII wherein X' represents a strong acid; and
R6 is Cj-Ce alkyl, substituted (Cj-C6) alkyl, (C3-C8) cycloalkyl, substituted C3-Cβ cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula Ilia, Ill'or III":
Figure imgf000005_0002
wherein
R6a, R*5, and R6c independently are H, halo or OR18;
R15, R16, and R17 independently are hydrogen, halo, (d-
C6) alkyl, OR18, O-aryl, NH2, NR18R19, N02, OP04H2, (Cj-Ce alkoxy)phenyl, Sbenzyl, C0NH2, C02H, P03H2, S02R23, or Z';
R18 and R19 independently are hydrogen or Cι-C6 alkyl;
R23 is hydrogen or (Cι-C3) alkyl;
Z is -(CH2)n- or (C3-C5) cycloalkyl; n is 0, 1, or 2; and Z' is an aromatic or substituted aromatic group.
Further, this invention provides a process for preparing an intermediate of Formula XII as defined supra, comprising contacting a compound of the formula XII'
Figure imgf000006_0001
XII' with a strong acid. In another aspect, this invention provides a new coupling process for preparing compounds of Formula XIII (known as Fragment A-B of the cryptophycins) :
Figure imgf000006_0002
XIII wherein
Ar is an aromatic or heteroaromatic group, or a substituted aromatic or heteroaromatic group; R60 is an alcohol protecting group; R3 is Cι-C6 alkyl; R* and R5 are H; or
R* and R5 together form a second bond; R6 is as defined supra; comprising contacting a compound of Formula XII as defined supra, with 1) a compound of Formula XV
Figure imgf000007_0001
XV wherein Ar, R3, R4, R5 and R60 are as defined supra;
2) an (RA) 2phosphinic halide, wherein RA is d-C6 alkyl, Cι-C6 aralkyl, or Ar; and 3) a base.
Furthermore, this invention provides an improved process for preparing a compound of Formula XIII, as defined supra, comprising reacting a compound of Formula XII, as defined supra, with a compound of formula XV as defined supra, in the presence of 1) the coupling reagent diphenyl chlorophosphate [ (PhO) 2P(0) Cl] ;and 2) an amine.
Carboxyl activation via phosphorous based reagents is an often used method for the synthesis of amides and related compounds. The particular method employed by Barrow et al . (J. Am. Chem. Soc. 1995, 117, 2479-2490) for the synthesis of the formula XIII compound wherein Ar=Ph, R3=Me, R60=TBS, R4 and R5-a second bond; and R6=3-chloro-4-methoxybenzyl (compound 4 infra ) utilized pentafluorophenyl diphenylphosphinic chloride (FDPP) as the coupling reagent.
That reaction only afforded compound 4 in 65% yield after silica gel chromatography. Thus, that method suffered from low yield (65%) and required FDPP preparation because it is not commercially available. The improved coupling procedure of this invention is advantageous in that it does not require preparation of the reagent [ (PhO) 2P (0) Cl] , and it gives higher yields (78%). Additionally, using (PhO)2P(0)Cl provides a significant cost advantage. In yet another aspect, this invention provides a process for preparing a compound of Formula I
Ar
Figure imgf000008_0001
wherein Ar , R3, R4, R5 and Rc are as defined supra;
R1 is halo, SR, OR, amino, mono or di- (Ci-Cβ-alkyl) amino, tri (Cι-C6-alkyl) ammonium, Cι-C6-alkylthio, di (C]-C6- alkyl) sulfoniu , Cι-C6-alkylsulfonyl, or Cι-C6- alkylphosphonyl; and
R2 is OH or SH; or R1 and R2 taken together form a second bond between C-18 and
C-19 or together form an epoxide, aziridine, episulfide, or cyclopropyl ring;
R is H, Cι-C6 alkyl, C]-C6 alkanoyl or Ar;
R7 is H, Cα-C6 alkyl, C2-C6-alkenyl, C2-C6-alkynyl, benzyl, or benzyl substituted with up to three substituents independently selected from Cι-C6-alkyl, halo, Cι-C6-alkoxy, amino or NR51R52; and
R8 is H or Cι-C6 alkyl; or
R7 and Rβ together form a C3-Cθ cycloalkyl ring; R51 and Rδ2 independently are C:-C3 alkyl;
R9 is H, Cι-C6 alkyl, C2-C6 alkenyl, C2-C6-alkynyl or (C,-C6 alkyl) C3-C5 cycloalkyl;
R10 is H or Cα-Ce alkyl;
X is 0, NH or {C1-C3 alkyl )N-; and Y is C, 0, NH, S, SO, S02 or (C1-C3 alkyl)N-; comprising contacting 1) a compound of Formula XVI
Figure imgf000010_0001
XVI wherein Ar, X, Y, R1 , R2, R3, R\ R5, Rb, R7, R8, R9, and R10 are as defined supra; with 2) an (RA) 2phosphinic halide, wherein RA is as defined supra; and
3) a base.
This invention also provides a process for preparing a compound of Formula XVII
Figure imgf000010_0002
XVII wherein R' is hydrogen or Cι-C6 alkyl; R7 and R8 are as defined supra; and Rp is tert-butoxycarbonyl or benzyloxycarbonyl; comprising contacting a compound of Formula XVIII
Figure imgf000011_0001
XVIII
wherein R'a is Cι-C6 alkyl, with a rhodium catalyst and hydrogen gas; and optionally hydrolyzing the product to obtain the compound wherein R' is hydrogen.
Processes where R7=R8 are preferred embodiments of this invention.
In another aspect, this invention provides a process for preparing a compound of Formula XIX
Figure imgf000011_0002
XIX wherein R7, R8, R9 and R10 independently are H or d-C6 alkyl; Rp is tert-butoxycarbonyl (BOC) or benzyloxycarbonyl; comprising contacting a compound of Formula XX
Figure imgf000012_0001
XX in the presence of
1) a catalytic quantity of Pd(PPh3)4, wherein the catalytic quantity is less than about four (4) mole percent, and
2) an allyl scavenger.
In addition, this invention provides an improvement in the process for preparing a compound of formula XX by coupling a Fragment D compound of the formula:
Figure imgf000012_0002
and a Fragment C compound of the formula:
Figure imgf000012_0003
wherein R7 and R8 are as defined supra, but provided R7 and R8 cannot be H, in an inert organic solvent; the improvement comprising using the coupling reagent l,l'- carbonyldiimidazole (CDI) . This process provides a significant improvement in yields of Fragment C compound. In addition, costs are reduced, and it is easier to remove unwanted by-products.
The phrase "catalytic quantity" refers to less than a stoichiometric amount, but an amount sufficient to achieve the desired results. The term is intended to have the meaning commonly understood in the art.
The term "alkyl" refers to an alkyl group with the designated number of carbon atoms. It may be saturated or unsaturated, and branched or straight chain. "Lower alkyl" means a C1-C5 alkyl group. Examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, propenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec- butyl, methyl-substituted butyl groups, pentyl, tert-pentyl, sec-pentyl, methyl-substituted pentyl groups and the like. "Substituted alkyl" refers to a Cι-C6 alkyl group that may include up to three (3) substituents containing one or more heteroatoms. Examples of such substituents are OH, NH2, C0NH2, C02H, P03H2 and S02R21 wherein R21 is hydrogen, d- C3 alkyl or aryl . The term "cycloalkyl" refers to a saturated C3-C8 cycloalkyl group. A "substituted cycloalkyl group" refers to a cycloalkyl group having up to three C1-C3 alkyl, halo, or OR21 substituents. The substituents may be attached at any available carbon atom. Cyclohexyl is an especially preferred cycloalkyl group. "Lower alkoxy" means a
Figure imgf000014_0001
alkyl group bonded to an oxygen atom.
The term "allyl" means a 2-propenyl group. The term "allyl scavenger" is commonly understood in the art. Preferred allyl scavengers are pyrrolidine, piperidine, morpholine, and 1, 3-dicarbonyl compounds. An especially preferred allyl scavenger is morpholine.
The term "halo" refers to Cl, Br, F, or I . The terms "aromatic group" and "heteroaromatic group" refer to common aromatic rings having 4n + 2 pi electrons in a monocyclic or bicyclic conjugated system. The term "aryl" refers to an aromatic group, and the term "aralkyl" refers to an aryl (Cι-Cc-alkyl) group. Examples of aromatic groups are phenyl, benzyl and naphthyl. Heteroaromatic groups will contain one or more oxygen, nitrogen and/or sulfur atoms in the ring. Examples of heteroaromatic groups include furyl, pyrrolyl, thienyl, pyridyl and the like. When the aromatic or heteroaromatic groups are substituted, they may have from one to three independently selected C1-C7 alkyl, Cι-C&-alkoxy or halo substituents. The substituents may be attached at any available carbon atom. Especially preferred heterocyclic groups are
Figure imgf000015_0001
wherein R2 is hydrogen or Cι-C6 alkyl. The term "amino protecting group" refers to a standard amino protecting group that is either acid labile or can be removed under mildly basic to neutral conditions. Such groups are well known in the art. [See, for example, J.F. . McOmie, "Protective Groups in Organic Chemistry", Plenum Press, (London and New York, 1973); Greene, T.W.
"Protecting Groups in Organic Synthesis", Wiley (New York, 1981) ] . Peferred amino protecting groups are acid labile. An especially preferred amino protecting group for compounds of Formula XVII is tert-butoxycarbonyl ("BOC") . When the R6 substituent in a Formula I compound contains an amino substituent, it must be protected using an amino protecting group. The term "alcohol protecting group" is one that is introduced during a portion of the synthetic process to protect an alcohol group that might otherwise react in the course of chemical manipulations. The group is then removed at a later stage of the synthesis. Reactions for the formation and removal of such protecting groups are described in a number of standard works, including the two references listed supra. A particularly useful alcohol protecting group is tert-butyldimethylsilyl (TBS) . The processes of this invention are preferably carried out in the presence of a solvent. Selection of an appropriate solvent is commonly understood in the art. An inert organic solvent, such as N, N-dimethylformamide (DMF) , ethyl acetate, dichloromethane, toluene or acetonitrile, or a mixture thereof, is recommended.
"Epoxide ring" means a three-membered ring whose backbone consists of two carbon and one oxygen atoms. "Aziridine ring" means a three-membered ring whose backbone consists of two carbon and one nitrogen atoms. "Episulfide ring" refers to a three-membered ring whose backbone consists of two carbon and one sulfur atoms.
Examples of methods of halogenation include the addition of hydrogen halides, free radical halogenation, etc. Such methods are known in the art. The term "strong acid" refers to an acid that has a pKa of 2 or less. A hydrohalic acid is most suitable. A preferred hydrohalic acid is hydrochloric acid. Other mineral acids, such as phosphoric and sulfuric, and organic acids, such as tosic and acetic, may also be used.
The term "base" has its accepted meaning. Thus, a base is a compound that yields hydroxyl ions in water or the negative ion of a solvent; or a base is any molecule or ion that can combine with protons or hydrogen ions, i.e. a proton acceptor. The term includes, but is not limited to, N,N-diisopropylethylamine, carbonates, and other tertiary amines.
Many of the cryptophycin compounds prepared by the processes of this invention are known. As used herein, the term refers to both known cryptophycins and to new cryptophycin compounds of Formula I, as defined supra . The process for preparing a formula XII compound that is a hydrochloride salt is illustrated by equation 1:
Figure imgf000017_0001
Other R6 groups can be substituted for the chloromethoxy- benzyl group. The first process for preparing the enamide fragment 4 is illustrated in equation 2. (eq. 2 )
Figure imgf000018_0001
Figure imgf000018_0002
In Eq. 2, TBS refers to a tert-butyldimethylsilyl group.
The improved process of preparing Fragment 4 is illustrated in Equation 3.
(PhO)2POCl 1 + 3 iPr2NEt,DMF 4 yield 78% (eq. 3)
Equations 2 and 3 are applicable to corresponding intermediates having various Ar, R60, and R6 groups.
Although DMF and N, N-diisopropylethylamine are the illustrated solvent-base used in equations 2 and 3, and in that of equation 4 infra, any nonparticipating solvent or solvent combination-base will be appropriate for the processes. Typical solvents include ethers, halogenated hydrocarbons, and esters. Typical bases include tertiary amines and carbonates. An especially preferred base for these processes is diisopropylethylamine .
The process for preparing an illustrative macrolactam of Formula I is illustrated by equation 4:
Figure imgf000019_0001
<eq. 4)
An especially preferred solvent for the process of eq. 4 is DMF. This process is especially useful because it provides improved yields. In addition, it makes it possible to use Ph2P(0)Cl, which is commercially available, to complete the macrolactamization.
The process for preparing a compound of Formula XVII wherein Rp=BOC is illustrated by Equation 5.
pi Rhodium cat. R'0 C
R _ _ -NHBOC BOC anhydr. R R
Figure imgf000020_0001
7 8 9
X=Br, I, OTs
(eq. 5) This process is especially useful because it is amenable to scale up, is cost effective, and provides good product yields .
Preparation of a specific compound of Formula XVII is illustrated by Equation 6.
H2(60 psi)
MeI/Cs2C03 Et0 r CN 5% Rh A12°3 Et02C^ ^.
Etθ?C. ^-CN *" ^NHBOC
DMF/0-25°C X B0C?0/THF
70°C
7a 9a
hydrolysis H c
^" ^NHBOC
10 (Fragment C )
(eq. 6)
Compound 8a is a known compound. It has been prepared by the reaction of ethyl cyanoacetate with methyl iodide in the presence of sodium ethoxide,a, and sodium hydride.c [a) Hessler, J.C. J. Am. Chem. Soc. 1913, 35, 990. b)
Biechler, S.S. and Taft, R.W. J. Am. Chem. Soc. 1957, 79, 4928. c) Thompson, H. W. and Swistok, J. J. Org . Chem. 1981, 46, 4907] .
Appropriate hydrolysis conditions for preparing Compound 10 from Compound 9a can be readily determined. Especially preferred hydrolysis agents are LiOH and NaOH.
The new allyl ester deprotection process is illustrated by Equation 7:
Figure imgf000021_0001
11
12
(eq. 7)
In the compounds in Equation 7, R , R , R , R9 and R10 have the meanings defined supra.
As illustrated, the Pd(PPh3), catalyst should be present in an amount less than about four (4) mole percent.
Preferably, the amount of Pd(PPh3)4 catalyst is less than two mole percent (2 %) . It is especially preferred that the amount of Pd(PPh3), catalyst is about two tenths mole percent (0.2%) or less. In addition, using less catalyst provides a significant cost advantage.
A preferred embodiment of the Equation 7 process is when R9 is isobutyl, and R10 is hydrogen. Especially preferred are compounds 11 and 12 wherein Rp=B0C, Rq=iBu, R10=H, and R7 and R8=Me (compounds 11a and 12a) or R7 and R8=H (compounds lib and 12b) .
An especially preferred allyl scavenger is morpholine.
Preferred solvents for the process of Equation 7 are tetrahydrofuran, acetone, alcohols, acetonitrile, and ethyl acetate. An especially preferred solvent is tetrahydrofuran . The use of the allyl ester as a protecting group for carboxylic acids is well known and has been the subject of reviews. Kocienski, P. J. Protecting Groups; Georg Thieme Verlag: Stuttgart, 1994; pp 139-154; Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesi s, 2nd Edition; John Wiley and Sons, Inc.: New York, 1991; pp 248-9; and Tsuji, J.; Mina i, I. Ace . Chem . Res . 1987, 20, 140-45. The allyl ester deprotection process in the literature uses ten (10) mole percent Pd(PPh3)4. Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S.; Moore, R. E.; Tius, M. A. J. Am. Chem. Soc . 1995, 117, 2479.
In the case of complex substrates such as 12 that are sensitive to the acidic and/or basic conditions used in subsequent isolation steps, isolation of pure product is problematic. The protecting group in 12 is generally not stable below pH 2-3, and the ester group of 12 can be cleaved by base (hydroxide) . Isolation and purification were even more significant issues for 12, because it could not be purified easily. Thus, there was a need to streamline the work-up and avoid exposure of 12 to aqueous acids or bases.
The present process provides surprisingly greater yields, fewer undesired impurities in the product, and allows isolation of acid-sensitive products without crystallization or chromatography of the product. Procedures A and B illustrate the isolation advantage of the new process over the prior art process:
PROCEDURE A (Barrowl) :
10 mo Pd ( PPh3) „ remove THF aq. HCl aq . NaHC03 pH to 3
11a »- •- »- ■» ». i2
10 eq morpholine add CH2C12 extraction extraction Et20
THF/22°C/ 1 h
PROCEDURE B (new process) :
0 .2 oi % Pd (PPh3) , remove THF aq. HCl
11a ». ». ». i2a
1 . 2 eq morpholine add hexane extraction
THF/22°C/ 1 h
'reference supra . Table 1 illustrates the yield advantage provided by the new process.
Table 1. Deprotection of Allyl Ester 11a.
Figure imgf000024_0001
The product of process A was contaminated with triphenylphosphine and triphenylphosphine oxide. These contaminants could be partially removed by eluting the crude product through silica gel with organic solvents. However, the acid adheres very strongly to silica gel, and this procedure was impractical for preparing large amounts of
12a.
In the new process, the amount of Pd(PPh3)4 catalyst was reduced from 10 to 0.2 mole percent (50 fold reduction) , and compound 12a was obtained in greater than 90% yield. Equally important, triphenylphosphine residues in the product were non-detectable by NMR spectroscopy . Surprisingly, the reaction was complete in less than one hour, even with the lower amounts of catalyst. Thus, Procedure B is simpler, more economical, and provides product with acceptable purity in 90+% yields.
The process of Equation 7 can be run at a temperature of from about zero (0) to about seventy (70) degrees C. A preferred temperature is about 25°C.
Table 2 summarizes the preparation of a number of Formula XIX compounds using this process:
TABLE 2: Preparation of Formula XIX Compounds by Allyl Ester Deprotection
Figure imgf000026_0001
Figure imgf000026_0002
19b methyl
19c ethyl
19d spirocyclopentyl
19e spirocyclohexyl
19f benzyl
19g n-propyl
19h i-butyl
Figure imgf000026_0003
Some preferred embodiments are set forth in the following tabular form wherein the features may be independently selected to provide preferred embodiments of this invention. The invention is in no way limited to the features described below:
A) an intermediate of Formula XII wherein R6 is halomethoxybenzyl ;
B) a compound of Formula XII wherein X1 is HCl; C) a process wherein R60 in intermediate XV is TBS;
D) a process wherein Ar in intermediate XV is phenyl; and
E) a process wherein R" and R5 in product I, together form a double bond. Appropriate starting materials and reagents to prepare the desired substrates and reagents for the intermediates and processes can be obtained using the guidance of the previous schemes and following examples. Most of the reagents are commercially available, and those which are not can be prepared using accepted chemical methods .
The necessary reaction time is related to the starting materials and operating temperature. The optimum reaction time for a given process is, as always, a compromise which is determined by considering the competing goals of throughput, which is favored by short reaction times, and maximum yield, which is favored by long reaction times.
To further illustrate the intermediates and processes of this invention, the following non-limiting examples are provided.
Example 1 a) Allyl ( 2 S) -2- [ [3- [ tert-Butoxycarbonyl) amino] -2 ' - dimethylpropanoyl] oxy] -4-methylpentanoate (11a) .
Figure imgf000028_0001
Fragment D 13 11a
To a solution of 1, 1 ' -carbonyldiimidazole ("CDI", 1346 g, 8.30 mol) in 3 L of THF was added a solution of compound 13 (1803 g, 8.3 mol) in 4 L of THF over 30 min. The reaction was stirred for 2 h at which time NMR analysis showed complete reaction of compound 13. Fragment D (1450 g, 7.54 mol) was added as a solid, and the reaction mixture was heated to approximately 70 °C for 16 h. The reaction mixture was cooled to 25 °C and concentrated in vacuo to give a suspension. Heptane (4 L) was added, and the mixture was extracted with 0.2 N HCl solution (6 L) to remove imidazole. The aqueous layer was extracted with 2 L of heptane. The combined organic layers were extracted successively with 0.2 N HCl solution (3 L) , deionized water (3 L), and brine (3 L) . The organic layer was dried (sodium sulfate) and concentrated in vacuo to give 2984 g of compound 11a as an oil. 1H NMR (CDCI3, 500 MHz) 6 0.94 (d,
3H, J = 8.4 Hz), 0.98 (d, 3H, J = 8.4 Hz), 1.27 (d, 6H, J = 5 Hz), 1.45 (s, 9H) , 1.71 (m, 3H) , 3.31 (m, 2H) , 4.66 (m,
2H) , 5.1 ( , 1H) , 5.3 ( , 3H) , 5.9 (m, 1H) . 13C NMR (CDCI3, 75 MHz) δ 176.4, 170.7, 156.4, 131.5, 119.1, 78.9, 70.9,
66.0, 48.7, 44.0, 39.6, 28.4, 24.9, 23.1, 23.0, 22.3, 21.6. IR (CHCI3) 3398, 2964, 1739, 1720, 1511, 1472, 1366, 1266,
1252 cm-1. MS { FD+ } m/z (relative intensity) 371 (100).
b) Preparation of 12a
To a solution of the 11a, obtained supra, in 8 L of THF was added Pd(PPh3)4 (3.0 g, 2.6 mmol). Morpholine (800 L, 9.15 mol) was then added dropwise over 30 min at 15-25 °C, and the reaction was then stirred at that temperature for 1.5 h. The reaction mixture was concentrated in vacuo to an oil, which was dissolved in 6 L of heptane. The heptane solution was extracted with 1 N HCl (9.8 L) . The aqueous layer was back-extracted with 2 L of heptane. The combined organic layers were washed with 3 L of brine, dried (sodium sulfate) , and filtered. The filtrate was stirred at room temperature and seeded with 200 mg of compound 12a. The product crystallized, and the slurry was stirred for 64 h (4 h is sufficient). The slurry was cooled to 0-10 °C for 3.5 h and filtered. The filter cake was washed with cold heptane (2 x 500 mL) and vacuum dried at 45-50 °C to give 2324 g (93% overall yield from Fragment D) of compound 12a as a white solid, mp 70-73 °C. TABLE 3: Preparation of Formula XX Intermediates
Figure imgf000030_0001
Conditions % Yield methyl CDI, 0.1N THF, 17h reflux 94 ethyl CDI, IN THF, 72h reflux 78 spirocyclopentyl CDI, 0.1N THF, 17h reflux 55 spirocyclohexyl CDI, 0.1N THF, 17h reflux 19 benzyl CDI, 0.1N THF, 17h reflux 21 n-propyl CDI, 0.1N THF, 17h reflux 0 n-propyl CDI, 0.4N PhMe, 17h reflux 59*
i-butyl CDI, 0.4N PhMe, 17h reflux 52*
* About 50%/ t unknown impurities
Example 2 (See Eq. 1)
Preparation of 3- (3-Chloro- -methoxyphenyl) -D-alanine 2,2,2- trichloroethyl ester hydrochloride salt (1) . To a 1000-mL 3-necked flask fitted with a calcium chloride drying tube and a mechanical stirrer and containing a solution of 2 (46.2 g, 100 mmol) in 370 L of ethyl acetate was added a solution of hydrochloric acid in ethyl acetate ( ca . 4.5 M, 800 mmol) . After stirring for 19 h at room temperature, the resulting thick white reaction was cooled to 0 °C and filtered. The collected solid was washed with cold ethyl acetate (1 x 90 mL) followed by drying in vacuo at 40 °C to provide 36.9 g (93%) of compound 1 as a white powder: mp 217-219 °C; [a]+3.1° (c 1.21, MeOH) ; IR (KBr) 2830 (m) , 1755 (s), 1502 (s) , 1282 (s), 1258 (s) , 1229 (s) , 814 (s) cm"1; 500 MHz *H NMR (DMSO-d6) δ 8.88 (br s, 3H) , 7.45 (d, 1H, J = 2.0 Hz), 7.28 (dd, 1H, J = 8.5, 2.0 Hz), 7.11 (d, 1H, J = 8.5 Hz), 5.01 and 4.96 (AB quartet, 2H, J = 12.2 Hz), 4.48 (t, 1H, J = 6.6 Hz), 3.84 (s, 3H) , 3.23 (dd, 1H, J = 14.4, 5.9 Hz), 3.17 (dd, 1H, J = 14.4, 7.3 Hz); 125 MHz 13C NMR (DMSO-d6) d 168.8, 154.7, 131.8, 130.3, 128.4, 121.9, 113.8, 95.2, 75.1, 57.0, 53.8, 35.3. Anal, calcd. for Cι2H14Cl5Nθ3: C, 36.26; H, 3.55; N, 3.52. Found: C, 36.24; H, 3.59; N, 3.44.
Example 3 (See Eq. 2)
Preparation of Ene-amide 4. A solution of acid 3 (551 mg,
1.53 mmol) in 3.1 mL of DMF was treated with N,N- diisopropylethylamine (799 mL, 4.58 mmol). Upon cooling to 0 °C, the mixture was treated with diphenylphosphinic chloride (306 mL, 1.60 mmol). After the reaction was stirred at 0 °C for 5 min and at room temperature for 30 min, hydrochloride salt 1 (668 mg as a solid, 1.68 mmol) was added over ca . 3 min. The mixture was allowed to stir for 1 h 15 min at which time the reaction was poured onto 20 mL of water and washed with diethyl ether (2 x 20 L) . The combined organic extracts were washed with IN hydrochloric acid (1 x 10 L) . The acid wash was extracted with diethyl ether (1 x 10 mL) ; and the combined organic extracts were dried (MgSO , filtered, and concentrated in vacuo to a yellow oil. Chromatography on 55 g of flash silica gel, eluting with ethyl acetate :hexanes (1:4), afforded 903 mg (84%) of compound 4 as a faint yellow foam. Example 4 (see Eq. 4) Preparation of Cryptophycin 51 (compound 6) .
To a solution of cryptophycin seco-acid 5 (671 mg, 0.963 mmol) in 10 mL of DMF was added N, N-diisopropylethylamine (503 mL, 2.89 mmol), followed by diphenylphosphinic chloride (202 mL, 1.06 mmol) . After being stirred at room temperature for 3 h, the reaction was diluted with ethyl acetate (50 mL) and washed successively with water (1 x 25 L) , 1 N HCl (1 x 25 mL) , saturated aqueous NaHC03 (1 x 25 mL) , and brine (1 x 25 mL) . Each aqueous layer was washed with ethyl acetate (1 x 25 mL) . The combined organic extracts were dried (Na2S04) , filtered, and concentrated in vacuo to a crude solid residue which was diluted with ethyl acetate. After standing at room temperature overnight, the mixture was filtered to provide 188 mg (30%) of 6 as a white solid. The filtrate was chromatographed over flash silica gel, eluting with ethyl acetaterhexanes (2:1 followed by 3:1) to afford another 304 mg (48%) of compound 6. Example 5 (See Eq . 6) a) Preparation of Ethyl 2-cyano-2-me hylpropanoate (8a) .
Cesium carbonate (4324 g, 13.27 mol) and DMF (2.25 L) were added to a 22 L flask with an overhead stirrer. Methyl iodide (2828 g, 19.9 mol), was added and the mixture was cooled to -10 °C under nitrogen. Ethyl cyanoacetate (750 g, 6.63 mol) was added over 30 min, keeping the reaction temperature below 30 °C. The cooling bath was removed, and the reaction mixture was stirred for 2 h. The reaction mixture was then filtered, and the salt cake was washed with 6 L of methyl tert-butylether (MTBE) . The filtrate was combined with 3 L of 0. IN HCl and the layers were separated. The aqueous layer was extracted with 3 L of MTBE. The combined organic layers were washed with 5% LiCl solution (2 x 3 L) , dried with sodium sulfate, and concentrated via distillation at atmospheric pressure to give compound 8a as a light yellow oil. The oil was vacuum distilled at 50-60 °C, 10 mm Hg to give 882 g (94% yield) of 2 as a colorless
oil. Η MR (CDC13, 500 MHz) δl.32 (t, 3H) , 1.60 (s, 6H) ,
4.26 (m, 2H) . 13C NMR (CDC13, 75 MHz) 5169.8, 120.9, 62.9, 38.7, 31.7, 24.9, 14.1. IR (CHC13) 3021, 2994, 2944, 2909, 2877, 2247, 1743, 1469, 1388, 1369, 1266, 1156 cm"1. MS {FD+} m/z (relative intensity): 142.1 (100). Anal. Calcd for C-,H„N02: C, 59.56; H, 7.85; N, 9.92. Found: C, 58.90; H, 7.39; N, 10.00. b) Preparation of Ethyl 3- [ (tert-butoxycarbonyl) amino] -2 ,2- dimethylpropanoate (9a) .
To a 500 L stainless steel autoclave were charged 5% rhodium on alumina (2.5 g) , BOC anhydride (8.4 g, 38.5 mmol), compound 8a (5.0 g, 35.4 mmol) and THF (140 mL) . The stirred mixture was placed under 60 psi hydrogen at 70 °C. After 16 h, an NMR spectrum of the reaction mixture showed the reaction was complete. The reaction mixture was allowed to cool to 25 °C, vented, and purged with nitrogen. The mixture was then filtered through a Celite pad and concentrated in vacuo to give 8.64 g (99% crude yield) of
compound 9a as an oil. lE NMR (CDC13, 500 MHz) δ 1.06 (s, 6H) , 1.15 (t, 3H) , 1.32 (s, 9H) , 3.1 (d, 2H) , 4.05 (m, 2H) , 5.0 (bs, 1H) . 13C NMR (CDC13, 300 MHz) δ 177.3, 156.3, 79.2, 60.8, 48.4, 43.7, 28.5, 23.1, 14.3. IR (CHC1 3691, 3457, 2983, 2936, 2875, 1714, 1602, 1509, 1473, 1367, 1312, 1240, 1155 cm-1. MS {FD+} m/z (relative intensity) 245.2 (100). Anal. Calcd. for C]2H23N04: C, 58.75; H, 9.45; N, 5.71. Found: C, 58.40; H, 8.95; N, 5.65.
c) Compound 10 To Compound 9a (164.2 g, approximately 670 mmol) was added 1.4 L of 5N NaOH, and the mixture was stirred under a nitrogen atmosphere until homogeneous (48 h) . CH2C12 (1.3 L) was added, and the mixture was cooled to 10 °C. The pH of the aqueous layer was adjusted to 3 by adding (dropwise) 1L of 6N HCl followed by 400 mL of IN HCl. The temperature was maintained below 20 °C. The mixture stirred for 20 min, and the layers were separated. The aqueous layer was extracted with 1 L of CH2C12. The organic layers were combined, dried over Na2S04 and concentrated in vacuo to give 116.8 g of a crude yellow solid. The solid was stirred in 400 mL of hexane for 4 h. The slurry was filtered and the solid dried to give 114.7 g (78% yield) of compound 10 as a
white solid, mp 115-16 °C. lE NMR (CDC13, 500 MHz) δ 1.23 (s, 6H) , 1.48 (s, 9H) , 3.26 (bs, 2H) , 5.09 (bs, 0.7 H) , 6.41 (bs, 0.3 H) , 11.68 (bs, 1H) . 13C NMR (CDC13, 75 MHz) δ 183.3, 181.7, 158.5, 156.4, 81.6, 79.6, 49.7, 48.1, 44.1, 43.7, 28.5, 23.0. IR (CHC13) 3315, 3004, 2542, 1895, 1700, 1648, 1414, 1367, 1350, 1278, 1157. MS {FD+} m/z (relative intensity) 173 (19), 218 (100). Anal. Calcd for C10H19NO4: C, 55.28; H, 8.81; N, 6.45. Found: C, 55.33; H, 8.59; N, 6.33. Example 6 (See Eq. 6) Large Scale Preparation. a) Compound 9a
To a 10 gallon stainless steel autoclave were charged 5% rhodium on alumina (390 g) , BOC anhydride (1363 g, 6.25 mol), compound 8a (prepared as described by Example 4) (779 g, 5.52 mol), and THF (20 L) . The stirred mixture was placed under 60 psi hydrogen at 70 °C. After 22 h, an NMR spectrum of the reaction mixture showed 83% conversion to 9a. Additional 5% rhodium on alumina catalyst (195 g) was added. The hydrogenation was continued for another 4 h, at which time NMR assay of the reaction mixture showed 98% conversion. The reaction mixture was allowed to cool to 25 °C, vented, and purged with nitrogen. The mixture was then filtered through a multi-plate filter and concentrated in vacuo to give 1173 g (87% yield) of compound 9a as an oil, which was used directly in the next step, b) Preparation of 3- [ (tert-Butoxycarbonyl) amino] -2 ,2- dimethylpropanoic acid (10) .
Two 22 L flasks were each charged with compound 9a (583 g, 2.38 mol), LiOH-H20 (204.5 g, 4.87 mol), THF (5.7 L) , and water (4.75 L) . The reaction mixtures were heated to 64 °C for 19 h. The mixtures were then cooled to 10 °C with an ice bath. Approximately 1 L of 6N HCl was added to each reaction mixture to bring the pH to 3-3.5. Each mixture was combined with 2.9 L of CH2C12, and the aqueous layers were separated. The aqueous layers were extracted with another 1.5 L portion of CH2C12. The combined organic layers were dried with sodium sulfate and concentrated in vacuo to give a white solid. The solid was slurried in 5 L of heptane for 1 h, filtered, and vacuum dried to give 830 g (80% yield) of compound 10 as a white solid, mp 114-116 °C. Anal. Calcd for CιoH19N04: C, 55.28; H, 8.81; N, 6.45. Found: C, 55.55; H, 8.77; N, 6.56. Example 7
(2S) -2-[ [3'-[ (tert-Butoxycarbonyl)amino]-2 ' ,2- dimethylpropanoyl]oxγ]-4-methylpentanoic Acid (12a).
Figure imgf000037_0001
12a
(RP=BOC )
A three-neck flask with an overhead stirrer was charged with compound 11a (23.92 g, 64.5 mmol), Pd(PPh3)4 (149 mg, 0.13
mmol), and dry THF (100 mL) . The mixture was cooled to 8 °C under nitrogen. Morpholine (6.8 mL, 77.4 mmol) in 10 mL of THF was add dropwise over 10 min. No exotherm was observed. The cooling bath was removed, and the solution was stirred for 1 h. The solvent was then removed from the reaction mixture under vacuum. The resulting viscous oil was dissolved in 250 mL of hexane, and 70 mL of 0.01N HCl was added. Then, IN HCl (77 mL) was added dropwise over 5 min. A small amount of yellow precipitate formed at the interface. The layers were separated, and the aqueous layer was extracted with 100 mL of hexane. The combined hexane layers were filtered to remove residual palladium complexes, dried with sodium sulfate, and concentrated in vacuo to obtain 21.3 g of 12a as a very viscous oil. (The NMR spectrum showed 6% (by weight) hexane in the oil; corrected yield of 12a = 94%.) [α]D = -34.2° (c 0.032, CHC13) . :H NMR
(CDC13, 500 MHz) δ 0.97 (d, J = 6.3, 3H) , 0.99 (d, J = 6.3 Hz, 3H) , 1.22 (d, J - 9.0 Hz, 6H) , 1.43 (s, 9H) , 1.75 ( ,
3H) , 3.31 (m, 2H) , 5.09 (dd, J = 9.7, 3.4 Hz, 1H) , 5.5 (bs, 0.7H), 6.16 (bs, 0.3H), 10.5 (bs, 1H) . 13C NMR (CDC13, 75
MHz) δ 176.6, 175.6, 156.8, 79.4, 70.6, 48.6, 44.0, 39.6,
28.4, 24.9, 23.1, 22.2, 21.5. IR (CHC13) 3691, 2963, 1710, 1512, 1151 cm"1. MS {FD+} m/z (relative intensity) 332 (100). Anal. Calcd. for C16H29N06: C, 57.99; H, 8.82; N, 4.23. Found: C, 58.05; H, 8.72; N, 4.13. Example 8
Preparation of [5S- (2E ,5R* , 6S* ,7E) ] -3-chloro-N- [5- [ [ (1 , 1- dimethy1ethyl) dimethylsilyl ] oxy] -6-methyl-l-oxo-8-phenyl- 2 ,7-octadienyl] -O-methyl-2 ,2 ,2-trichloroethyl ester D- Tyrosine (4) .
A solution of acid 3 (130 mg, 0.361 mmol) in 720 μL of DMF was treated with N,N-diisopropylethylamine (188 μL 1,08 mmol), followed by diphenyl chlorophosphate (82 μL , 0.396 mmol) . After the mixture had stirred for 1 h, hydrochloride salt 1 (157 mg, 0.395 mmol) was added as a solid. The mixture was allowed to stir for 2 h 45 min at which time the reaction was diluted with diethyl ether (15 ml) and washed with IN hydrochloric acid (10 L) , saturated sodium bicarbonate solution (10 mL) , and brine (10 mL) . The organic phase was dried (MgS04) , filtered, and concentrated in vacuo to a yellow oil. Chromatography on 15 g of flash silica gel, eluting with ethyl acetate :hexanes (1:2), afforded 199 mg (78%) of compound 4 as a faint yellow oil.

Claims

Claims
1. A compound of Formula XII
Figure imgf000040_0001
XII wherein X' represents a strong acid; and
R6 is Cι-C6alkyl, substituted (Cι-C6) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula Ilia, Ill'or III":
Figure imgf000040_0002
wherein
R6a, R6*, and R6c independently are H, halo or OR18; R15, R, and R17 independently are hydrogen, halo, (Cj- C6) alkyl, OR18, O-aryl, NH2, NR18Rιq, N02, OP04H2, (Cι-C6
alkoxy)phenyl, Sbenzyl, CONH2, C02H, P03H2, S0-R2S, or Z'; R18 and R19 independently are hydrogen or Cι-C6 alkyl; R23 is hydrogen or (Cι-C3) alkyl; Z is -(CH2)n- or (C3-C5) cycloalkyl; n is 0, 1, or 2; and
Z' is an aromatic or substituted aromatic group.
2. A compound of Claim 1 wherein R6 is halomethoxybenzyl .
3. A process for preparing a compound of Formula XII
Figure imgf000041_0001
XII wherein X' represents a strong acid; and
R6 is Cι-C6alkyl, substituted (Cι-C6) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula Ilia, Ill'or III":
Figure imgf000041_0002
wherein
,βc and R ,6c independently are H, halo or OR 18
R ,15, rR,16, and R independently are hydrogen, halo, (d- C6) alkyl, OR18, O-aryl, NH2, NR18Rιq, NO,, OP04H?, (C1-C6 alkoxy)phenyl, Sbenzyl, CONH2, C02H, P03H2/
Figure imgf000042_0001
or Z';
R18 and R19 independently are hydrogen or Cι~C6 alkyl;
R23 is hydrogen or (C1-C3) alkyl;
Z is -(CH2)n- or (C3-C5) cycloalkyl; n is 0, 1, or 2; and
Z' is an aromatic or substituted aromatic group; comprising contacting a compound of formula XII'
Figure imgf000042_0002
XII with a strong acid.
4. A process of Claim 3 wherein R6 is halomethoxybenzyl .
5. A process of Claim 3 wherein the acid is hydrochloric acid.
6. A process for preparing a compound of Formula
XIII
Figure imgf000043_0001
XIII wherein
Ar is an aromatic or heteroaromatic group, or a substituted aromatic or heteroaromatic group;
R60 is an alcohol protecting group;
R3 is Cι-C6 alkyl;
R* and R5 are H; or
R* and R5 together form a second bond;
R6 is Cι-C6alkyl, substituted (Cι-C6) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula
Ilia, Ill'or III":
Figure imgf000043_0002
wherein
R6a, ", and R6c independently are H, halo or OR18; R , R , and R independently are hydrogen, halo, (Ci- Ce) alkyl, OR18, O-aryl, NH2, NR18R19, N02, OP04H2, (Cι-C6 alkoxy)phenyl, Sbenzyl, CONH2, C02H, P03H2, S02R23, or Z';
R18 and R19 independently are hydrogen or C-C6 alkyl; R23 is hydrogen or (Cι-C3) alkyl; Z is -(CH2)n- or (C3-C5) cycloalkyl; n is 0, 1 or 2; and Z' is an aromatic or substituted aromatic group; comprising contacting 1) a compound of the Formula XII
Figure imgf000044_0001
wherein X' represents a strong acid; with 2) a compound of the Formula XV
Figure imgf000044_0002
XV
3) an (RA)2 phosphinic halide, wherein RA is Cj-Ce alkyl, Ci- C6 aralkyl or Ar; and 4) a base.
7. A process of Claim 6 wherein X' is HCl.
8. A process of Claim 6 wherein R60 is TBS.
9. A process of Claim 7 wherein the base is N,N- diisopropylethylamine .
10. A process for preparing a compound of Formula I
Figure imgf000045_0001
wherein
Ar is an aromatic or heteroaromatic group, or a substituted aromatic or heteroaromatic group;
R1 is halo, SR, OR, amino, mono or di- (Cι-C6-alkyl) amino, tri (Cι-C6-alkyl) ammonium, Cι-C6-alkylthio, di (d-C6- alkyl) sulfonium, Cι-C6-alkylsulfonyl, or Cι-C6- alkylphosphonyl; and
R2 is OH or SH; or
R1 and R2 taken together form a second bond between C-18 and C-19 or together form an epoxide, aziridine, episulfide, or cyclopropyl ring;
R is H, Cι-C6 alkyl, Cι~C6 alkanoyl or Ar;
R3 is Cι-C6 alkyl;
R4 and R5 are H; or R4 and R5 together form a second bond;
R6 is Cι-C6alkyl, substituted (Cι-C6) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula Ilia, Ill'or III'
Figure imgf000046_0001
wherein R6a, R6", and R6° independently are H, halo or OR18;
R7 is H, Cι-C6 alkyl, C2-C6-alkenyl, C2-C6-alkynyl, benzyl, or benzyl substituted with up to three substituents independently selected from d-C6-alkyl, halo, C]-C6-alkoxy, amino or NR51R52; and Rβ is H or Cι-C6 alkyl; or
R7 and R8 together form a C3-Ce cycloalkyl ring;
R51 and R52 independently are C1-C3 alkyl;
R9 is H, Cj-Ce alkyl, C2-C6 alkenyl, C2-C6-alkynyl or (d~C6 alkyl) C3-C5 cycloalkyl; R10 is H or d-C6 alkyl;
X is 0, NH or (C1-C3 alkyl) -; and
Y is C, 0, NH, S, SO, S02 or (C1-C3 alkyDN-; comprising contacting 1) a compound of Formula XVI
Figure imgf000047_0001
XVI with 2) an (RA)2 phosphinic halide, wherein RA is d~C6 alkyl; and 3) a base.
11. A process of Claim 10 wherein the base is N,N- diisopropylethylamine .
12. A process of Claim 11 wherein R6 is halomethoxybenzyl .
13. A process for preparing a compound of Formula XVII
Figure imgf000047_0002
XVII wherein R' is hydrogen or Cι~C6 alkyl;
R7 is H, Cι-C6 alkyl, C2-C6-alkenyl, C2-C6-alkynyl, benzyl, or benzyl substituted with up to three substituents independently selected from Cι-C6-alkyl, halo, d-C6-alkoxy, amino or NR51R52; and
R8 is H or d-C6 alkyl; or
R7 and R8 together form a C3-C8 cycloalkyl ring; and Rp is tert-butoxycarbonyl or benzyloxycarbonyl; comprising contacting a compound of the Formula XVIII
Figure imgf000048_0001
XVIII with a rhodium catalyst.
14. A process of Claim 13 wherein the rhodium catalyst is rhodium on alumina.
15. A process for preparing a compound ofFormula XIX
Figure imgf000048_0002
XIX
wherein
R7, R8, R9 and R10 independently are H or CI-CG alkyl; and
Rp is tert-butoxycarbonyl or benzyloxycarbonyl; comprising contacting a compound of Formula XX
Figure imgf000048_0003
XX in the presence of 1) a catalytic quantity of less than about four (4) mole percent of Pd(PPh3)4 and 2) an allyl scavenger.
16. A process of Claim 15 wherein the catalytic quantity is less than about two (2) mole percent.
17. A process of Claim 16 wherein the catalytic quantity is about two tenths mole percent (0.2%) .
18. A process of Claim 16 wherein the allyl scavenger is morpholine.
19. In the process for preparing a compound of formula XIII
Figure imgf000049_0001
XIII wherein Ar is an aromatic or heteroaromatic group, or a substituted aromatic or heteroaromatic group;
R60 is an alcohol protecting group;
R3 is Ci-C6 alkyl;
R* and R5 are H; or R4 and R5 together form a second bond;
R6 is Ci-C6alkyl, substituted (Cι-C6) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula
Ilia, Ill'or III":
Figure imgf000050_0001
wherein
R , R , and RBC independently are H, halo or OR18;
R15, R1S, and R17 independently are hydrogen, halo, (d-
C6) alkyl, OR18, O-aryl, NH2, NR18R19, N02, OP04H2, (Cι-C6 alkoxy)phenyl, Sbenzyl, CONH2, C02H, P03H2, S02R23, or Z';
R18 and R19 independently are hydrogen or d-C6 alkyl;
R23 is hydrogen or (d~C3) alkyl;
Z is -(CH2)n- or (C3-C5) cycloalkyl ; n is 0, 1 or 2; and
Z' is an aromatic or substituted aromatic group; comprising by reacting 1) a compound of formula XII
Figure imgf000050_0002
XII wherein X' represents a strong acid; and 2) a compound of formula XV
Figure imgf000051_0001
XV
2) with a coupling reagent and 3) an amine, the improvement which comprises using diphenyl chlorophosphate as the coupling agent.
20. In the process for preparing a compound of formula XX
Figure imgf000051_0002
XX wherein R7 is H, Cι~C6 alkyl, Ci-Ce-alkenyl, C2-C6-alkynyl, benzyl, or benzyl substituted with up to three substituents independently selected from d-C6-alkyl, halo, d-C6-alkoxy, amino or NR51R52; and
Rβ is H or Cι-C6 alkyl ; or R7 and R8 together form a C3-C8 cycloalkyl ring;
R9 is is H, Cι-C6 alkyl , C2-C6 alkenyl , C2-C6-alkynyl or (Cα-C6 alkyl ) C3-C5 cycloalkyl ;
R10 is H or Cι-C6 alkyl ; and Rp is tert-butoxycarbonyl or benzyloxycarbonyl; by coupling a Fragment D compound of the formula:
Figure imgf000052_0001
and a Fragment C compound of the formula:
Figure imgf000052_0002
provided that R7 and R8 cannot be H; in an inert organic solvent; the improvement comprising using the coupling reagent l,l'- carbonyldii idazole .
21. An improvm ent of Claim 21 wherein R1 and R8 are methyl.
22. An improvement of Claim 21 wherein Rp is BOC.
PCT/US1997/015703 1996-09-06 1997-09-05 Process and novel intermediates WO1998009955A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002263764A CA2263764A1 (en) 1996-09-06 1997-09-05 Process and novel intermediates
EP97941446A EP0929535A4 (en) 1996-09-06 1997-09-05 Process and novel intermediates
AU43352/97A AU4335297A (en) 1996-09-06 1997-09-05 Process and novel intermediates
JP10512955A JP2001502298A (en) 1996-09-06 1997-09-05 Methods and new intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2552196P 1996-09-06 1996-09-06
US60/025,521 1996-09-06

Publications (1)

Publication Number Publication Date
WO1998009955A1 true WO1998009955A1 (en) 1998-03-12

Family

ID=21826566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015703 WO1998009955A1 (en) 1996-09-06 1997-09-05 Process and novel intermediates

Country Status (5)

Country Link
EP (1) EP0929535A4 (en)
JP (1) JP2001502298A (en)
AU (1) AU4335297A (en)
CA (1) CA2263764A1 (en)
WO (1) WO1998009955A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034252A2 (en) * 1998-12-07 2000-06-15 Eli Lilly And Company Process for the preparation of cryptophycin derivatives
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522746A (en) * 2009-04-01 2012-09-27 レツク・フアーマシユーテイカルズ・デー・デー Method for dimethylation of active methylene groups

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567834A (en) * 1969-06-16 1971-03-02 Bristol Myers Co Method of producing sedation
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739120A (en) * 1986-08-21 1988-04-19 The Dow Chemical Company Process for the hydrogenation of nitriles to primary amines
DE3904119A1 (en) * 1989-02-11 1990-08-16 Hoechst Ag POLYMER FIXED METHOTREXATE, METHOD FOR PRODUCTION AND USE
IT1239029B (en) * 1989-10-12 1993-09-20 Poli Ind Chimica Spa PROCESS FOR THE PREPARATION OF 3- (L-PYROGLUTAMYL) -L- THIAZOLIDIN-4-CARBOXYLIC ACID AND ITS DERIVATIVES.
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
DE69413559T2 (en) * 1993-12-28 1999-04-22 Rhodia Fiber & Resin Intermediates, Courbevoie CATALYST FOR HYDROGENATING NITRILES IN AMINES, METHOD FOR PRODUCING THE CATALYST AND METHOD FOR HYDROGENATING USING THE SAME
TJ347B (en) * 1995-03-07 2002-10-06 Univ Hawaii Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
EP0792875B1 (en) * 1996-02-27 2001-05-09 Eli Lilly And Company Cryptophycin derivatives and their use as anti-microtubule agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567834A (en) * 1969-06-16 1971-03-02 Bristol Myers Co Method of producing sedation
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0929535A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034252A2 (en) * 1998-12-07 2000-06-15 Eli Lilly And Company Process for the preparation of cryptophycin derivatives
WO2000034252A3 (en) * 1998-12-07 2000-12-07 Lilly Co Eli Process for the preparation of cryptophycin derivatives
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer
EP2289549A2 (en) 1999-10-01 2011-03-02 Immunogen, Inc. Immunoconjugates for treating cancer

Also Published As

Publication number Publication date
CA2263764A1 (en) 1998-03-12
JP2001502298A (en) 2001-02-20
EP0929535A4 (en) 2001-05-23
AU4335297A (en) 1998-03-26
EP0929535A1 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
US7989653B2 (en) Exo- and diastereo-selective syntheses of himbacine analogs
EP3248969B1 (en) Process for the preparation of n-[3-(aminomethyl)oxetan-3-yl]carbamate intermediates
US8163933B2 (en) Clean, high-yield preparation of S,S and R,S amino acid isosteres
JP4310271B2 (en) Method for the synthesis of acyloxyalkyl derivatives of GABA analogs
KR101294432B1 (en) 3-alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
RU2418785C2 (en) Method of obtaining renin inhibitors
JPS626718B2 (en)
EP0929535A1 (en) Process and novel intermediates
US6610874B2 (en) Processes and compositions for the production of chiral amino-nitriles
US20190256453A1 (en) Methods and intermediates for synthesizing sk1-i
US6573388B1 (en) Ethylaziridine derivatives and their preparation methods
WO1998008812A1 (en) Process for preparing pharmaceutical compounds
EP1309550A1 (en) Optically active aziridine-2-carboxylate derivatives and a process for preparing them
JPH09323960A (en) Production of 3-amino-1,2-oxirane
JP2004509879A (en) Production process of optically active epoxide
KR20030055304A (en) Process for the preparation of protected 1-(1-aminoalkyl)-oxiranes
JP2004026652A (en) beta-ALKOXYACRYLONITRILE DERIVATIVE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09029206

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2263764

Country of ref document: CA

Ref country code: CA

Ref document number: 2263764

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997941446

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 512955

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997941446

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997941446

Country of ref document: EP